Mersana Therapeutics to Present at Upcoming Investor Conferences
May 26 2022 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that members of
management will present at three upcoming investor conferences.
Details are as follows:
Cowen’s 3rd Annual
Oncology Innovation Summit |
Format: |
|
Fireside
Chat |
Date/Time: |
|
Thursday, June 2, 2022, at 1:00 p.m. Eastern Time |
Jefferies Global Healthcare Conference |
Format: |
|
Presentation |
Date/Time: |
|
Friday, June 10, 2022, at 10:00 a.m. Eastern Time |
The JMP Securities Life Sciences Conference |
Format: |
|
Presentation |
Date/Time: |
|
Wednesday, June 15, 2022, at 3:00 p.m. Eastern Time |
A live webcast of these events will be available on the
Investors & Media section of Mersana’s website at
www.mersana.com. Archived replays will be available for
approximately 90 days following the events.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage
biopharmaceutical company using its differentiated and proprietary
ADC platforms to rapidly develop novel ADCs with optimal efficacy,
safety and tolerability to meaningfully improve the lives of people
fighting cancer. Mersana’s lead product candidate, upifitamab
rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is
being studied in UPLIFT, a single-arm registrational trial in
patients with platinum-resistant ovarian cancer, as well as in
UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combination
with other ovarian cancer therapies. Mersana’s early-stage programs
include XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056,
a STING-agonist ADC developed using the company’s Immunosynthen
platform and targeting a novel epitope of human epidermal growth
factor receptor 2 (HER2). In addition, multiple partners are using
Mersana’s platforms to advance their ADC pipelines. Mersana
Therapeutics was recently named among the 2021 Top Places to Work
in Massachusetts by The Boston Globe. Mersana routinely posts
information that may be useful to investors on the “Investors and
Media” section of its website at www.mersana.com.
Contact:Jason Fredette
617-498-0020jason.fredette@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2024 to May 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From May 2023 to May 2024